Kornimate/medical-research-clean huggingface dataset:
establishing alpha-synuclein rt-quic assay as a diagnostic technique in rem sleep behaviour disorder

Conditions: Sleep Disorder Rem Sleep Behavior; Parkinson's Disease, Lewy Body

Summary: we hypothesise that a real-time quaking induced conversion assay for the detection of pathological alpha-synuclein (α -syn rtquic) can be used to differentiate between cases of idiopathic rem-sleep behaviour disorder (rbd) and rbd that is symptomatic of prodromal α-synucleinopathies.

this study will be the largest analysis of cerebrospinal fluid (csf) α-synuclein in rapid eye movement behaviour disorder (rbd) patients to date. in line with the the national cjd research \& surveillance unit (ncjdrsu)'s recent inclusion of a positive rt-quic for pathological prion protein in the diagnostic criteria for creutzfeldt-jakob disease (cjd) \[1\], we aim to deploy this novel method to establish it as an accurate research and diagnostic resource in the assessment and prognosis of rbd. this research is transformative and has the potential to change practice. currently, there is no simple method with high sensitivity and specificity available which can identify patients who will go on to develop an α - synucleinopathy. clinical assessment of a panel of markers (e.g. postuma et al. 2015) are time-consuming and impractical in normal clinical settings, with the majority of patients presenting to sleep physicians, geriatricians, and non-specialised neurology clinics, both publicly and privately. this has a major impact on counselling strategies for rbd patients, appropriate follow-up, trials of novel neuro-protective agents in alpha-synucleinopathies before full-blown phenotype is manifest and enhancing understanding of pathways involved in rbd out-with the dopaminergic system. rbd is a common, sometimes fatal disease (through injury to self/others) and treatments are indiscriminate regarding aetiology with limited evidence-base. a simple test using csf (analogous to measuring csf-orexin levels to diagnose narcolepsy+cataplexy) with high sensitivity and specificity is ideal. thus, we believe that the central thesis of our work will not only inform subsequent behavioural, genetic and neuroimaging characterisation of our established rbd cohort, but will also translate the α-syn rt-quic concept into evidence-based and effective clinical practice.

Eligibility criteria:
inclusion criteria: * patients diagnosed with rapid eye movement behaviour disorder (rbd) using the international classification of sleep disorders version 3 (icsd-3) criteria \[18\] - patients aged 18 years and over - patient able to give written informed consent exclusion criteria: * rbd secondary to medication or withdrawal state. - \<18 years old - inability to give written informed consent - contraindication to lumbar puncture procedure (e.g. patients taking warfarin)

Keywords: rembd rem behavioural disorder prodromal α-synucleinopathies
a study to evaluate lower extremity sleeve and pump device to treat hemiparesis

Conditions: Upper Extremity Weakness; Stroke

Summary: the primary purpose of this study is to establish that application of a sequential compression device (scd) and lower extremity (le) sleeve applied to a hemi-paretic upper extremity is safe.

studies has shown that passively stimulating the arm with vibration can improve sensory and motor recovery and movement. researchers want to expand on this with a more advanced stimulation but in a device that is already routinely used. the scd is normally used to prevent blood clots. it uses pressure to keep blood moving in the leg. it is routinely used in hospitals across the country. while it does this it warms and even vibrates the leg giving many types of stimulation to the limb and to the brain. this stimulation may help improve recovery further, at marginal cost, while possibly reducing the chances of blood clots in an immobile limb.

Eligibility criteria:
inclusion criteria: * patients admitted to mayo clinic/jacksonville, post-stroke with a hemiparetic upper extremity. * able to provide consent of participation by self-agreement. * patients with a hemiparetic upper extremity will be determined using the nih motor arm subsection from the nih scale and score a 1-4. * patients who have received thrombolytic therapeutic medicine \> 13 hours (per site specific policy) will not be excluded from inclusion in this study. * patients who score \> 13 on the bims to ensure intact cognition. exclusion criteria: * inability to provide consent of participation. * subjects with aphasia or the inability to effectively communicate their pain consistently. * questionable reliability scoring \< 13 on the bims, has an existing invasive line (picc line, iv, av fistula or av graft); recent surgery or vein ligation in the involved extremity. * recent skin graft in the involved extremity. * confirmed dvt in the affected. * upper extremity including axillary or subclavian veins; open or active wounds or infection in the involved extremity. * upper extremity ischemia, gangrene, cellulitis or severe arteriosclerosis in the affected upper extremity. * status-post axillary lymph node dissection on the involved side; congestive heart failure (chf) acute exacerbation; acute edema of unknown etiology in the involved upper extremity. * subjects with extreme deformity of the affected upper extremity. * subjects with an acute kidney injury. * subjects who are hemodynamically unstable 1,7,17. * patients who have received thrombolytic therapeutic medicine administered \< 13 hours (per site specific policy) prior to application of scd sleeve.
intra-procedural 360-degree display for performing percutaneous liver tumor ablation

Conditions: Percutaneous Tumor Ablation

Summary: medical images used to guide treatment of tumor(s) are presently displayed on flat-panel monitors (like screens used with computers). this protocol will evaluate, using a new headset to view the images in true 3d ("360 degrees"), while using standard flat panel monitors as usual (in accordance with standard of care). the headset is combined with a mini-global positioning system (gps)-like system to help navigate to treat tumor(s). this evaluation is to show that the headset has potential to provide guidance and navigation information that can improve the treatment of tumor(s) with heat.

this protocol will clinically evaluate new 3d holographic guidance and navigation for percutaneous ablation of solid tumors to ultimately overcome limitations of displaying images on 2d flat-panel monitors ("flat screens"). 3d holographic percutaneous ablation (3d hpa) provides real-time, 360° visualization for guidance and navigation of tracked interventional instruments augmented to the operative site. in this preliminary protocol, 3d hpa will be evaluated as an adjunct to flat-screen display of conventional images used for guidance (ultrasound, fluoroscopy, ct), in accordance with standard of care.

Eligibility criteria:
inclusion criteria: * not pregnant * willing and able to give informed consent prior to enrollment. this includes media release form. * has met all criteria to undergo percutaneous tumor ablation. exclusion criteria: * not willing or able to give informed consent * patients with pacemakers or automated implantable cardioverter defibrillator (aicds).

Keywords: hololens 3d holographic guidance
study to investigate the efficacy and the safety of m518101 in plaque psoriasis patients

Conditions: Plaque Psoriasis

Summary: this study is to evaluate the efficacy and safety of m518101 and the dose relationship among two doses of m518101 and placebo in male and female plaque psoriasis patients.

this study is to evaluate the efficacy and safety of m518101 and the dose response relationship among two doses of m518101 and placebo in male and female plaque psoriasis patients and to confirm the persistence of the effect of m518101.

Eligibility criteria:
inclusion criteria: 1. who are able and willing to give signed informed consent 2. who are male or females aged 18 years or older with plaque psoriasis confirmed by the investigator. 3. who have less than 20% of body surface area (bsa) afflicted with plaques 4. who are neither pregnant nor breast-feeding, nor plan to become pregnant during the study. exclusion criteria: 1. who have a history of allergy to vitamin d3 derivative preparations. 2. who have a history of relevant drug hypersensitivity. 3. who have a history of contact dermatitis induced by a topical medicine. 4. who are pregnant or lactating. 5. who have any renal or hepatic insufficiency, or clinically significant cardiac, renal or hepatic disease. 6. who are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests. 7. who have clinically relevant history or presence of any disease or surgical history other than psoriasis which is likely to affect the conduct of the study. 8. whose serum calcium levels exceed the upper limit of reference range 9. who have used any investigational medicinal product and/or participated in any clinical study within 60 days before the day of signing the icf. 10. who have been treated with systemic therapy within 2 weeks before the day of signing the icf and during the wash-out period. 11. who have been treated with biologics within 5 half-lives of the biologics before the day of randomization. 12. who have been treated with topical therapy during the wash-out period.
subarachnoid hemorrhage recovery and galantamine

Conditions: Subarachnoid Hemorrhage

Summary: the purpose of this study is to examine the effects of the study drug--galantamine-on patients with subarachnoid hemorrhage (sah). the study will examine how patients with sah will tolerate the study drug and how it may improve brain functioning in patients after sah.


Eligibility criteria:
inclusion criteria: * spontaneous subarachnoid hemorrhage * presentation to hospital within 72 hours of symptoms * fisher grade 3 hemorrhage (thick subarachnoid clot) on initial computed tomography (ct) scan * hunt and hess grade 1-5 at time of randomization * presence of a cerebral aneurysm on computed tomographic angiography (cta) or angiogram for which clipping or coiling is possible * ability to obtain medication within 36 hours of presentation exclusion criteria: * subarachnoid hemorrhage (sah) due to causes other than aneurysm rupture (trauma, arteriovenous malformation (avm), mycotic aneurysms, moyamoya) * pre-existing disability with modified rankin scale (mrs) score ≥2, * renal disease as defined by creatinine clearance less than 9 milliliters/min * history of severe hepatic impairment (child-pugh score of 10-15) * history of chronic obstructive pulmonary disease (copd) or asthma * history of dementia * co-morbid conditions likely to complicate therapy, including clinically significant arrhythmia, acquired immune deficiency syndrome (aids), autoimmune disease, malignancy, and expected mortality within 72 hours * expected mortality within 72 hours as determined by pi, treating neurointensivist and neurosurgeon. (clinically manifested by no attempt at securing aneurysm) * females who are pregnant.
efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing crohn's disease

Conditions: Crohn Disease; Fistula Perianal

Summary: the use of mesenchymal stem cells is considered a novel and promising therapeutic option for patients with perianal fistulizing crohn's disease. however, due to limited clinical data, this multicentre, nationwide study aimed to assess its clinical efficacy in closing complex anal fistula.

fifteen applications in 14 patients (3 male, 11 female) with complex anal fistulas treated in three tertiary hospitals in austria were included between october 2018 and april 2021. injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells (cx601 - darvadstrocel, alofisel®) was performed in each patient. closure of the external fistula opening without secretion by finger compression was defined as success.

Eligibility criteria:
inclusion criteria: * patients aged 18 and older who had a non-active or mildly active luminal cd with complex fistula with a maximum of two internal and three external fistulas exclusion criteria: * rectovaginal fistulas * rectal and/or anal stenosis * active proctitis * diverting stomas * an abscess (\<2cm) that was not drained at the fistula preperation visit
glucose metabolism in pregnant women with a history of bariatric surgery, as well as three to six months after delivery.

Conditions: Bariatric Surgery Candidate; Pregnancy Complications; Pregnancy Related; Glucose Metabolism Disorders

Summary: in this study glucose metabolism of pregnant women with a history of bariatric surgery, obese pregnant women and normal weight pregnant women was investigated. three to six months after delivery the assessment of glucose metabolism was repeated and the amount of ectopic lipids in the liver, heart and muscle was measured.

in this study pregnant women with a history of bariatric surgery, normal weight and obese pregnant women were invited to participate. between the 24th and the 28th week of pregnancy an oral glucose tolerance test (ogtt), as well as an intravenous glucose tolerance test (ivgtt) was conducted. three to six months after delivery the examinations were repeated. in addition the ectopic lipid content in the liver, heart and the muscle was measured with 1h-magnetic resonance spectroscopy and imaging three to six months post partum. the aim of this study was to compare the glucose metabolism during pregnancy between the three groups as well as to investigate the changes three to six months after delivery.

Eligibility criteria:
inclusion criteria: * pregnant women with a history of rygb operation * normal weight pregnant women * obese pregnant women exclusion criteria: * infectious diseases such as hepatitis b or c, hiv, hematological diseases, acute infections, liver disease, renal disease, cancer

Keywords: glp-1 ectopic lipids
auto/allo tandem transplant for relapsed b-nhl

Conditions: Non Hodgkin Lymphoma

Summary: the investigators plan to perform a retrospective review of patients with poor risk relapsed/refractory b-nhl having received hsct and targeted immunotherapy at the maria fareri children's hospital between january 1, 2012 and june 1, 2015. the investigators will review the clinical records and collect the data with de-identified medical information from our hsct clinical research database.

the investigators will obtain the following information from the patient's medical records: clinical factors including age at presentation, gender, clinical presentation, laboratory and pathology data, lymphoma diagnosis, clinical staging criteria, anti-cancer therapy as well as supportive care medicines, complications of therapy (adverse events graded from ctcae v4.0), and hematopoietic stem cell transplantation therapy (chemotherapy, donor source, cell dose), course (engraftment, gvhd, chimerism), and follow-up (disease status).

Eligibility criteria:
inclusion criteria: * this analysis will include all children, adolescents, and young adults less than 29 years old with a histologically confirmed diagnosis of b-nhl treated at the maria fareri children's hospital exclusion criteria: * none
d-dimer determined anticoagulation intensity in patients with mechanical valve replacement

Conditions: Heart Valve Disease

Summary: the optimal intensity of oral anticoagulation in china patients undergoing mechanical valve replacements is still controversial due to the different risk profiles of thrombophilia and bleeding in chinese patients. elevated d-dimer could reflect a pro-thrombogenic or prothrombotic state, and thus might be used to decide the intensity of oral anticoagulation. this study was to evaluate whether elevated d-dimer levels could help to determine the intensity of oral anticoagulation in patients with mechanical heart valve prostheses.

background: the optimal intensity of oral anticoagulation in china patients undergoing mechanical valve replacements is still controversial due to the different risk profiles of thrombophilia and bleeding in chinese patients. elevated d-dimer could reflect a pro-thrombogenic or prothrombotic state, and thus might be used to decide the intensity of oral anticoagulation. objective: this study was to evaluate whether elevated d-dimer levels could help to determine the intensity of oral anticoagulation in patients with mechanical heart valve prostheses. methods: a single-center, prospective study was performed. 748 patients with mechanical valve replacement who had received oral anticoagulation. the patients were randomly assigned to three groups the intensity of anticoagulation for group one was standard intensity (inr:2.5-3.5). the intensity of anticoagulation for group two was kept at low intensity without adjustment (inr:1.8-2.6), and for group three , the intensity of anticoagulation maintained at low level initiatively (inr:1.8-2.6), d-dimer testing were analyzed two times at 3 month later. in case of d-dimer level elevated, adjusted the intensity of anticoagulation to standard level. the endpoint of the study was the subsequent thromboembolic and major bleeding during an average follow-up of 2 years.

Eligibility criteria:
inclusion criteria: 1. age\>18years,male or female without pregnancy; 2. suffered the mechanical valves replacement in wuhan asia heart hospital; 3. the operation type was mitral valve replacement or double valves replacement(aortic and mitral valve replacement). exclusion criteria: patients with following diseases within 3 months. 1. deep venous thromboembolism 2. pulmonary embolism 3. aortic dissection 4. stroke 5. cerebral hemorrhage 6. myocardial infarction

Keywords: mechanical valves replacement inr d-dimer thromboembolic events
the effectiveness of kinesio taping in patients with chronic low back pain

Conditions: Chronic Low-back Pain

Summary: the objective of this study is to determine the effectiveness of kinesio taping (kt) with conventional physical therapy (cpt) - transcutaneous electrical nerve stimulation (tens) and supervised exercise therapy and cpt in the management of clbp.

chronic low back pain (clbp) is one of the most common causes of chronic disability which leads to major social and economic consequences. the role and effectiveness of the kinesio taping (kt) and conventional physical therapy (cpt) are evident from the existing literature but no comparison was found on the combination of other physical therapy techniques such as supervised exercise therapy and transcutaneous electrical nerve stimulation (tens) with clbp in the kingdom of saudi arabia

Eligibility criteria:
inclusion criteria: * pain caused by mechanical/nonspecific low back pain. * degeneration of the spine and intervertebral disc. * the visual analog scale of pain 4 and above * low back pain for at least three months exclusion criteria: * physical therapy treatment is taken in the past 6 months period * previous spinal surgery with fixation * structural anomalies * spinal cord compression * severe osteoporosis * acute infections * severe cardiovascular or metabolic diseases * pregnant women

Keywords: low back pain chronic kinesio taping tens exercises
genetic study to identify gene mutations in participants previously enrolled in clinical trial nci-99-c-0053 who have von hippel-lindau syndrome or are at risk for von hippel-lindau syndrome

Conditions: Kidney Cancer; Von Hippel-lindau Syndrome

Summary: rationale: the identification of gene mutations in individuals who have or are at risk for von hippel-lindau syndrome may allow doctors to better determine the genetic processes involved in the development of cancer. purpose: this genetic study is finding gene mutations in participants with von hippel-lindau syndrome or who are at risk for developing von hippel-lindau syndrome.

objectives: * obtain laboratory identification and confirmation of research results for gene mutations in participants previously enrolled in nci-99-c-0053 who have von hippel-lindau (vhl) syndrome or who are at risk for vhl syndrome. * determine genotype status in these participants. outline: participants submit a blood or buccal sample for genetic mutation analysis. participants may receive genetic counseling and/or the results of genetic testing, if desired. projected accrual: a maximum of 260 participants will be accrued for this study.

Eligibility criteria:
disease characteristics: * prior enrollment in the von hippel-lindau (vhl) syndrome epidemiology study nci-99-c-0053 * meets 1 of the following criteria: * diagnosis of vhl syndrome * at risk of vhl syndrome * family member of patient with vhl syndrome * vhl syndrome genotype is not known patient characteristics: age * adult performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: renal cell carcinoma von hippel-lindau syndrome
intestinal microecological dysregulation caused by appendectomy increases the risk of colorectal cancer

Conditions: Colorectal Neoplasms

Summary: as a good niche for bacterial growth, appendix plays a very important role in maintaining and protecting intestinal symbiotic flora. appendectomy will lead to intestinal microecological disorders. therefore, we put forward the hypothesis that "appendectomy leads to intestinal microecological disorders and then increases the risk of colorectal cancer". in this study, the feces of normal controls, appendectomy and patients with colorectal cancer were collected, and the specific changes of intestinal flora after appendectomy were explored in detail from the level of family, genus and species by macrogenomic sequencing. then through functional gene analysis, metabolic pathway analysis and other methods to explore the molecular mechanism of colorectal cancer risk changes and the changes of microflora involved, and verified by mouse fecal bacteria transplantation animal experiment.


Eligibility criteria:
inclusion criteria: * patients undergoing appendectomy due to appendicitis; * 6-36 months after appendectomy; * patients with no obvious abnormality observed by colonoscopy; * age between 20 and 85. exclusion criteria: * a. any history of malignancy or disease * any inflammatory bowel disease (ibd) prior to study inclusion; * antibiotics and hormone drugs taken within the last three months; * patients with severe systemic diseases (severe diabetes, hypertension or autoimmune diseases, etc.); * severe clinical symptoms of digestive tract (severe diarrhea, constipation, purulent disease, etc.) within half a year.
effect of treadmill based aerobic exercise intervention on menstruation and quality of life in women with polycystic ovarian syndrome

Conditions: Polycystic Ovary Syndrome; Irregular Menses

Summary: this study will be carried to investigate the effect of aerobic exercise on menstrual regularity and quality of life in pco women

this study will be carried out on sixty females with polycystic ovarian syndrome (pcos) patients will be randomly assigned into two equal groups: control group (30 women) will receive low caloric diet 1200 cal/day) while study group (30 women) will receive the same diet regime and treadmill aeobic exercise

Eligibility criteria:
inclusion criteria: * women with pco * age from17 to 28 years * bmi 25- 30 exclusion criteria: * asthma and chronic respiratory disease * congenital spinal problems * cardiopulmonary disease * physical impairments